


What is claimed is:

1. A pharmaceutically effective composition which comprises the following compound:



wherein R_1 and R_2 are each independently selected from the group consisting of: alkyls, hydrogen, aryls, aromatic compounds, amines, sulfur-containing alkyl groups, sulfur-containing aryl groups, and heterocyclic compounds.


2. The composition of claim 1 in which R_1 comprises an aromatic ring containing group.

3. The composition of claim 1 in which R_2 comprises an alkane.

4. The composition of claim 3 in which the alkane comprises a carbon chain having less than about 6 carbon atoms.


5. The composition of claim 4 in which the alkane comprises a t-butyl group.

6. A pharmaceutically effective composition comprising:




wherein R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , and R_9 each are independently selected from the group consisting of: alkyls, hydrogen, aryls, aromatic compounds, amines, sulfur-containing alkyl groups, sulfur-containing aryl groups, and heterocyclic compounds.


7. An N-alpha trifluoroethyl amino acid compound having the general chemical formula




8. The compound having the structure represented as:




9. The compound having the structure represented as:




10. The compound having the structure represented as:




11. The compound having the structure represented as:



12. The compound having the structure represented as:




13. The compound having the structure represented as:





16. A polypeptide, comprising:




wherein R₁, R₂, R₃, and R₄ are each independently selected from the group consisting of: alkyls, hydrogen, aryls, aromatic compounds, amines, sulfur-containing alkyl groups, sulfur-containing aryl groups, and heterocyclic compounds; and

wherein n is an integer greater than or equal to 1.

17. A lipophilic protein having enhanced affinity for lipophilic tissues that is adapted for crossing the blood brain barrier in mammals, the lipophilic protein being prepared by reacting a first protein with a -CF₃-containing compound to form a lipophilic protein.

18. The compound comprising:



19. The compound comprising:

